NSE: SAGILITY | BSE: 544282

Mid-range Performer

Download real time

43.12 0.54 (1.27%)

25.51% Fall from 52W High

5.7M NSE+BSE Volume

NSE 01 Oct, 2026 11:34 AM (IST)

20,185.9

Market Cap

High in industry

Beta 1Year

Average volatility

Sagility Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for SAGILITY, BSE:544282 Sagility Ltd.

Search Inside the pdf :

Sagility Ltd.

28 Sep 2026

43.12

1.27%

Higher MLR among US payers accelerating outsourcing

Buy: Sagility Ltd.

Target

Motilal Oswal

Sagility’s practices are designed to manage and improve critical healthcare operations across the payer and provider ecosystem. These capabilities span the full healthcare value chain, combining deep domain expertise with operational execution to deliver measurable outcomes.

Motilal Oswal decreased Buy price target of Sagility Ltd. to 54.0 on 28 Sep, 2026.

Sagility Ltd.

20 Sep 2026

43.12

1.27%

Scale, specialization, structural tailwinds align; initiate with BUY

Buy: Sagility Ltd.

Emkay

We initiate coverage on Sagility with BUY and 12M forward TP of Rs55, at 18x Sep-28E adjusted EPS, implying an upside of 20%.

Sagility Ltd. is trading above its 150 day SMA of 42.0

Sagility Ltd.

22 Jul 2026

43.12

1.27%

Sagility Q1FY27 Result Update

Buy: Sagility Ltd.

Aditya Birla Money Limited

We raise our revenue estimates by 0.8%/2.7%/4.7% for FY27E/FY28E/FY29E, factoring in CareSeed consolidation and sustained revenue momentum. However, we revise our EPS estimates by -6.7%/-1.8%/+1.8% for FY27E/FY28E/FY29E to incorporate the ~120bps FY27 wage-related margin headwind. While near-term margins may remain under pressure, CareSeed enhances the company's quality and care-management capabilities while expanding its mid-market client base. We maintain our BUY rating with a revised TP of Rs 58 (earlier Rs 61). At 17.1x FY27E EPS, valuations remain attractive with scope for re-rating. We remain positive on...

Sagility Ltd. is trading above its 150 day SMA of 42.0

Sagility Ltd.

22 Jul 2026

43.12

1.27%

Strong FY26; FY27 to be a year of normalization

Buy: Sagility Ltd.

Target

Motilal Oswal

Sagility’s 1QFY27 revenue rose 15.2% YoY in CC (beat on estimates) and INR revenue stood at INR19,635m (est: 18,860m), rising 27.6% YoY.

Sagility Ltd. has an average target of 54.20 from 6 brokers.

Sagility Ltd.

22 Jul 2026

43.12

1.27%

Good execution in a seasonally weak quarter

Buy: Sagility Ltd.

Target

ICICI Securities Limited

Sagility reported a slight beat on I-Sec’s Q1FY27 revenue growth estimate and an in-line EBITDA margin. Revenue growth was led by the payer segment, as the provider segment’s traction has slowed over the last two quarters.

Motilal Oswal decreased Buy price target of Sagility Ltd. to 54.0 on 28 Sep, 2026.

Sagility Ltd.

27 Mar 2026

43.12

1.27%

SAGILITY LIMITED

Buy: Sagility Ltd.

Target

Geojit BNP Paribas

Sagility Ltd. is a healthcare-focused, technology-enabled solutions provider primarily serving U.S. health insurers (payers), along with hospitals, physicians, and medical device companies (providers). Headquartered in Bengaluru, the company operates 33 delivery centers across India, the U.S., and other global markets. In Q3FY26, ~90% of its revenue...

Number of FII/FPI investors decreased from 223 to 190 in Jun 2026 qtr

Sagility Ltd.

27 Mar 2026

43.12

1.27%

Sagility (SAGILITY IN) Analyst Meet Update Navigating policy & AI disruption with domain solutions Not Rated

Not Rated: Sagility Ltd.

Prabhudas Lilladhar

Create domain specific agentic AI solutions to expand TAM Sustain revenue momentum while maintaining margins We attended Sagility's Investor Day, where management outlined how US healthcare policy changes and AI adoption are reshaping its business, and how the company is turning these headwinds into growth opportunities. Policy-driven margin pressures on payer clients are accelerating the shift toward cost-saving outsourcing, where Sagility's human in the loop agentic solutions, built on two decades of domain expertise across both payers and providers, can reduce client costs and effort by ~30%...

Number of FII/FPI investors decreased from 223 to 190 in Jun 2026 qtr

Sagility Ltd.

27 Mar 2026

43.12

1.27%

Analyst meet update: AI - a growth accelerator

Buy: Sagility Ltd.

Target

ICICI Securities Limited

Sagility hosted its first analyst meet (on 25th Mar’26). It highlighted that AI continues to be a key growth driver, woven into most of its solutions and platforms.

Motilal Oswal decreased Buy price target of Sagility Ltd. to 54.0 on 28 Sep, 2026.

Sagility Ltd.

26 Mar 2026

43.12

1.27%

Structural complexities and inefficiencies in the US healthcare system remain a key tailwind

Buy: Sagility Ltd.

Target

Motilal Oswal

Growth strategies are clearly anchored around: cost transformation driven by demand from US payers; capability-led differentiation, including AI.

Sagility Ltd. is trading above its 150 day SMA of 42.0

Sagility Ltd.

28 Jan 2026

43.12

1.27%

A stronger FY26 exit in sight; raises revenue growth guidance

Buy: Sagility Ltd.

Motilal Oswal

Sagility’s 3QFY26 revenue rose 29.1% YoY in Constant Currency (CC), higher than our estimate of 21% YoY CC. EBIT margin stood at 19.7%, and adj. PAT came in at INR3.2b (up 7.3% QoQ and 23.0% YoY), well above our estimate of INR2.8b.

Motilal Oswal decreased Buy price target of Sagility Ltd. to 54.0 on 28 Sep, 2026.